Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.

The disposition of mesalazine from the azo compounds sulphasalazine and olsalazine (Dipentum) and from the slow-release mesalazine drugs Pentasa, Asacol, and Salofalk was studied in 20 patients with inflammatory bowel disease. Ten of them had diarrhoea, and 10 had normal stools. On the last 2 days of a 7-day maintenance treatment with each of the study drugs urine and faeces were collected for determination of mesalazine, acetyl-mesalazine, and unsplit azo compound. In patients with and without diarrhoea the urinary and the faecal excretion of acetyl-mesalazine was lowest during treatment with olsalazine. The proportion of acetyl-mesalazine in faeces was highest during treatment with Pentasa in both groups. The presence of diarrhoea was associated with a decrease in the proportion of acetyl-mesalazine in faeces during treatment with all drugs, not significant only for Pentasa. The proportion of unsplit azo compound in faeces increased in the case of diarrhoea to almost 50%. It is concluded that in patients with inflammatory bowel disease diarrhoea substantially influences the disposition from all these drugs except Pentasa.
AuthorsM C Rijk, A van Schaik, J H van Tongeren
JournalScandinavian journal of gastroenterology (Scand J Gastroenterol) Vol. 27 Issue 10 Pg. 863-8 (Oct 1992) ISSN: 0036-5521 [Print] NORWAY
PMID1359629 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Aminosalicylic Acids
  • Delayed-Action Preparations
  • Drug Carriers
  • Sulfasalazine
  • Mesalamine
  • olsalazine
  • Adult
  • Aged
  • Aminosalicylic Acids (chemistry, pharmacokinetics, therapeutic use, urine)
  • Delayed-Action Preparations (standards)
  • Diarrhea (etiology)
  • Drug Carriers
  • Feces (chemistry)
  • Female
  • Gastrointestinal Transit
  • Humans
  • Inflammatory Bowel Diseases (complications, drug therapy, urine)
  • Male
  • Mesalamine
  • Middle Aged
  • Sulfasalazine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: